Literature DB >> 10849259

Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients.

C M Rodrigues1, D Brites, F Serejo, A Costa, F Ramalho, M C De Moura.   

Abstract

The mechanisms of hepatocyte damage and the events that lead to high rates of chronic liver disease in hepatitis C virus (HCV) infection remain unclear. Recent in vitro studies have suggested that the HCV core protein may disrupt specific signalling pathways of apoptosis. This prompted us to study patients with chronic HCV infection to: determine the extent of apoptosis in the liver; evaluate whether clinical and biochemical data are correlated with histological findings; and to investigate if apoptosis is related to the histological activity of the disease. Twelve patients with chronic hepatitis C were included in the study. Liver histology was scored by using the histological activity index (HAI) of Knodell et al. DNA fragmentation was assessed in liver tissue by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labelling (TUNEL) assay. Routine methods were used to determine serum markers of liver disease. Bile acids were measured in serum and liver by gas chromatography. Patients were placed, according to their HAI score, into group A (3.8 +/- 0.3) or group B (7.8 +/- 0.8) (P < 0.01). Liver enzymes tended to be higher in group B patients than in patients of group A. Levels of toxic bile acids in serum were greater in patients than in controls (P < 0.01). Chenodeoxycholic acid values were slightly higher in serum and liver of patients in group A. Liver biopsies with low HAI scores showed an increased rate of apoptosis (18.0 +/- 4.0 apoptotic cells per field) compared to those with higher HAI scores (6.6 +/- 2.1, P < 0.05) or to controls (3.5 +/- 0.4, P < 0.01). Hence, less severe liver disease, associated with lower histological grades and biochemistries, as well as increased levels of chenodeoxycholic acid, induces an expanded apoptotic response. The lower apoptotic rate in advanced liver disease may be associated with the high incidence of hepatocellular dysplasia/neoplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849259     DOI: 10.1046/j.1365-2893.2000.00219.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody.

Authors:  Jo L McPartland; Muna Ali Guzail; Charles H Kendall; James Howard Pringle
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

2.  Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species.

Authors:  Yuichi Hara; Keisuke Hino; Michiari Okuda; Takakazu Furutani; Isao Hidaka; Yuhki Yamaguchi; Masaaki Korenaga; Kui Li; Steven A Weinman; Stanley M Lemon; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

Review 3.  Apoptosis in animal models of virus-induced disease.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

4.  Cre-estrogen receptor-mediated hepatitis C virus structural protein expression in mice.

Authors:  Batbayar Tumurbaatar; Yixiao Sun; Tehsheng Chan; Jiaren Sun
Journal:  J Virol Methods       Date:  2007-07-12       Impact factor: 2.014

5.  Foxp3 expression in liver correlates with the degree but not the cause of inflammation.

Authors:  Matthaios Speletas; Nikoletta Argentou; Georgios Germanidis; Themistoclis Vasiliadis; Konstantinos Mantzoukis; Kalliopi Patsiaoura; Pavlos Nikolaidis; Vaios Karanikas; Konstantinos Ritis; Anastasios E Germenis
Journal:  Mediators Inflamm       Date:  2011-05-25       Impact factor: 4.711

Review 6.  Bile acids for viral hepatitis.

Authors:  W Chen; J Liu; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.